+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies



Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies



Bmc Cancer 7: 217



14-3-3sigma is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3sigma is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3sigma expression in patients with haematological malignancies. We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological malignancies for 14-3-3sigma expression with real-time RT-PCR. We also examined protein levels by Western blot analysis and DNA methylation status of the 14-3-3sigma gene by methylation-specific PCR analysis of bisulfite-treated DNA. In addition, mutations of p53 gene were identified by RT-PCR-SSCP analysis and the expression levels of 14-3-3sigma were compared with those of other cell-cycle inhibitor genes, CDKN2A and ARF. The expression levels of 14-3-3sigma mRNA in almost all cell lines were low and comparable to those in normal hematopoietic cells except for 2 B-cell lines. On the contrary, 14-3-3sigma mRNA was aberrantly overexpressed frequently in mature lymphoid malignancies (30 of 93, 32.3%) and rarely in acute leukemia (3 of 35, 8.6%). 14-3-3sigma protein was readily detectable and roughly reflected the mRNA level. In contrast to epithelial tumors, methylation status of the 14-3-3sigma gene was not associated with expression in hematological malignancies. Mutations of p53 were identified in 12 patients and associated with lower expression of 14-3-3sigma. The expression levels of 14-3-3sigma, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth. 14-3-3sigma, an epithelial cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies. This is the first report of aberrant 14-3-3sigma expression in non-epithelial tumors in vivo. Since the significance of 14-3-3sigma overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3sigma gene in non-epithelial as well as epithelial tumors is warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051304614

Download citation: RISBibTeXText

PMID: 18036248

DOI: 10.1186/1471-2407-7-217


Related references

Involvement of aberrant DNA methylation in hematological malignancies. Japanese Journal of Clinical Hematology 55(10): 1709-1714, 2014

Expression of aberrant antigens in hematological malignancies: A single center experience. Pakistan Journal of Medical Sciences 34(2): 457-462, 2018

MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies. Leukemia 12(3): 414-421, 1998

MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies. Leukemia (basingstoke). 12(3): 414-421, Ch, 1998

Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes, Chromosomes & Cancer 46(9): 796-804, 2007

Twist as a new prognostic marker in hematological malignancies. Clinical and Translational Oncology 18(2): 113-124, 2016

Leukocytosis in non hematological malignancies--a possible tumor-associated marker. Journal of Cancer Research and Clinical Oncology 111(1): 54-58, 1986

Experimental and theoretical investigations of the reactions NH(X 3Sigma-) + D(2S)-->ND(X 3Sigma-) + H(2S) and NH(X 3Sigma-) + D(2S)-->N(4S) + HD(X 1Sigmag+). Journal of Chemical Physics 122(20): 204313, 2005

Molecular analysis of more than 140 gene fusion variants and aberrant activation of EVI1 and TLX1 in hematological malignancies. Annals of Hematology 96(10): 1605-1623, 2017

Three-color flowcytometric analysis of mature and immature hematological malignancies. A guideline of the Dutch Foundation for Immunophenotyping of Hematological Malignancies (SIHON). Journal of Biological Regulators and Homeostatic Agents 18(3-4): 313-326, 2005

BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Research 61(6): 2409-2412, 2001

MiR-155 as a diagnostic and prognostic marker in hematological and solid malignancies. Neoplasma 61(3): 241-251, 2014

Ceruloplasmin as a tumor marker in pediatric hematological malignancies. Pathology Research & Practice 185(1): 114, 1989

Cell-free DNA - Minimally invasive marker of hematological malignancies. European Journal of Haematology 99(4): 291-299, 2017

The soluble interleukin-2 receptor: a new humoral marker in hematological malignancies. Acta Haematologica Polonica 22(2): 327-330, 1991